Kao Corporation vs Rohto Pharmaceutical Co., Ltd.
Kao holds the stronger position because its moat runs deeper and its income is growing faster than its sales even while named rivals such as Unilever, P&G, Shiseido, and L'Oreal press on it, whereas Rohto's lighter competitive pressure traces to activist governance concerns rather than actual customer defection.
Kao Corporation
Japanese maker of household, hygiene, and cosmetics brands like Bioré and Curél
Rohto Pharmaceutical Co., Ltd.
127-year-old Japanese OTC pharma maker behind Hada Labo and Melano CC skincare
Dimension by dimension
| Dimension | Kao Corporation | Rohto Pharmaceutical Co., Ltd. |
|---|---|---|
| Staying power of the core product | Rated defensible for now, reflecting live competitive contests in cosmetics and personal care. | Rated Hard to displace, with no visible sign of customers leaving for other brands. |
| Exposure to AI absorbing the product | AI is unlikely to absorb Kao's hygiene, household, and cosmetics lines. | AI is unlikely to absorb Rohto's skincare and OTC pharma lines. |
| How easily a giant could copy them | A larger company could possibly replicate Kao's products. | A larger company could possibly replicate Rohto's products. |
| Pressure from rivals | Kao faces direct pressure from Unilever and P&G globally and from Shiseido and L'Oreal in cosmetics. | Rohto's competitive pressure is tied to activist governance concerns, not to customers switching to competitors. |
| Depth of competitive protection | Kao's competitive protection spans hygiene, household, and cosmetics categories with global scale, assessed July 2026 as the deeper of the two. | Rohto's competitive protection rests on its OTC pharma and skincare lines, assessed July 2026 as narrower than Kao's. |
| Financial footing | FY2025 sales rose 3.7% to ¥1,688.6 billion, operating income rose 11.9% to ¥164.1 billion, and net income rose 11.4% to roughly ¥120 billion, showing income growing faster than sales. | Consolidated sales reached a record ¥343.7 billion, with a market capitalization of ¥531 billion. |
Questions people ask
- Rohto vs Kao, which is better positioned for the AI era?
- Neither company's core products are exposed to AI absorption, so the difference comes down to competitive strength and finances. Kao has a slightly deeper moat and income growing faster than sales, while Rohto carries less real rival pressure but smaller scale.
- Which company has stronger financials, Rohto or Kao?
- Kao is far larger, with FY2025 sales of ¥1,688.6 billion versus Rohto's record ¥343.7 billion, and Kao's operating income and net income both grew faster than its sales. Rohto's numbers show record sales and a ¥531 billion market cap but no comparable income growth figures are given.
- Could a big company copy either Rohto or Kao?
- Both are rated as possible targets for a larger company to copy, so neither has an edge on this point.
- Is AI a threat to Rohto or Kao's products?
- Both are rated unlikely to have their products absorbed by AI, since skincare, OTC pharma, and household hygiene goods are physical products rather than information services.
Other comparisons with these companies